Cancer treatment in India could become more affordable for many families following a major government decision to bring down the prices of selected anti-cancer medicines.
The National Pharmaceutical Pricing Authority (NPPA) has released revised Maximum Retail Prices (MRPs) for 543 cancer medicine brands. The new prices are scheduled to take effect from November 9, 2026.
The move follows the government's decision to limit trade margins to 30% of the MRP for 137 identified non-scheduled anti-cancer medicines. The aim is to reduce excessive mark-ups across the medicine supply chain and make essential cancer treatments more accessible.
According to the Department of Pharmaceuticals, the wider initiative could bring down the prices of covered medicines by up to 70% and save patients and their families approximately ₹2,500 crore annually. These are government estimates, however, and individual savings will depend on the specific medicines and treatment plans involved.
For families already dealing with hospital bills, diagnostic tests, consultations and repeated treatment cycles, even a reduction in medicine costs could make a meaningful difference.
However, not every cancer medicine is included in this revision. Patients should understand which products are covered, when the new prices apply and how to check the correct MRP before purchasing their medicines.
NPPA REVISES PRICES FOR 543 CANCER DRUG BRANDS
On October 28, the NPPA published an updated price list covering 543 anti-cancer medicine brand entries. The list includes price information submitted by pharmaceutical companies up to October 27 and may be updated as more companies provide revised details.
The latest decision focuses on non-scheduled anti-cancer medicines, which were not previously subject to the same ceiling-price regulations that apply to scheduled essential medicines.
Under the Trade Margin Rationalisation (TMR) policy, the maximum trade margin for 137 identified medicines has been restricted to 30% of the MRP. In simple terms, the measure is intended to prevent excessive mark-ups as medicines move from manufacturers through distributors and retailers to patients.
The selected medicines include immunotherapy treatments and drugs used for different types of cancer. Some of the medicines mentioned in the government announcement include denosumab, pegfilgrastim and bevacizumab.
It is important to understand that this decision does not cover every cancer medicine sold in India. The revised prices apply to the specific notified medicines, brands and formulations included in the price list.
SOME CANCER MEDICINES SEE MAJOR PRICE REDUCTIONS
The revised NPPA list includes significant price reductions for several cancer medicine brands. Some examples highlighted by the government include:
Medicine / Brand
Earlier MRP
Revised MRP
Anarzole — Anastrozole, 1 mg, 10 tablets
₹695.76
₹73.00
Azacytin — Azacitidine, 100 mg injection
₹6,337.00
₹1,495.04
Bevacizab — Bevacizumab, 100 mg/4 ml vial
₹21,767.70
₹5,930.13
Dasanat 20 — Dasatinib, 60 tablets
₹2,812.50
₹1,085.93
Debrumab — Denosumab, 60 mg injection
₹22,031.25
₹5,941.00
Samtepa — Thiotepa, 100 mg injection
₹80,071.86
₹7,150.33
Source: Press Information Bureau.
Some of these reductions are particularly striking. The listed price of Samtepa, for example, has dropped from more than ₹80,000 to around ₹7,150 per vial. Similarly, Anarzole is now listed at ₹73 for a pack of 10 tablets, compared with its earlier price of ₹695.76.
These examples show how the government's trade-margin restrictions can significantly reduce the retail prices of selected medicines.
However, patients should remember that lower prices for individual drugs do not necessarily translate into the same percentage of savings on their total treatment expenses.
WHY HAS THE GOVERNMENT INTRODUCED THE PRICE CAP?
The financial burden of cancer treatment goes well beyond the cost of medicines. Patients often need multiple treatment cycles, regular investigations, hospital visits and supportive medication. Over time, these expenses can put considerable pressure on household finances.
The Department of Pharmaceuticals said its market analysis found that non-scheduled anti-cancer medicines had an average price mark-up of around 170%, with some products recording mark-ups of 700% or more.
The government believes that restricting these margins will help reduce unnecessary costs and improve access to cancer treatment.
This is not the first time such an initiative has been introduced. In 2019, the government capped trade margins on 42 selected non-scheduled cancer medicines. According to official figures, that exercise reduced the MRPs of 526 brands by up to 91% and resulted in estimated annual savings of ₹984 crore.
The latest revision expands the approach to a wider range of medicines.
Alongside price reductions, the government has asked manufacturers to maintain existing production and supply levels for the notified formulations. This is intended to ensure that patients continue to have access to their prescribed medicines even after the new prices come into effect.
WHAT PATIENTS NEED TO KNOW BEFORE NOVEMBER 9
The revised MRPs are expected to apply from November 9, 2026. Patients and caregivers can take a few practical steps to make sure they benefit from the changes.
1. Check the exact medicine and brand
Not every medicine will receive a price reduction. The revised MRP applies to specific notified brands, strengths, formulations and pack sizes. Always check the exact details before purchasing.
2. Verify the updated MRP
Patients can refer to the NPPA's revised price list or use the Pharma Sahi Daam app to check medicine prices. The list may be updated as pharmaceutical companies submit additional information.
3. Ask pharmacies and hospitals about the new prices
Retail pharmacies, hospitals and medical institutions have been directed to follow the revised prices from November 9. Patients can ask for an updated bill and check whether the new MRP has been applied.
4. Keep prescriptions and payment receipts
Holding on to medical bills and prescriptions makes it easier to compare medicine prices and raise concerns if a pharmacy charges more than the applicable MRP.
5. Discuss affordable alternatives with your oncologist
If a prescribed medicine or brand is not included in the revised list, patients can ask their oncologist or hospital pharmacist whether a suitable, lower-cost alternative is available.
6. Never change treatment without medical advice
A lower-priced medicine does not automatically mean it is suitable for every patient. Patients should never stop, delay or replace prescribed cancer medication without consulting their treating doctor.
The government has also instructed pharmaceutical companies to publish updated price lists and share them with retailers and hospitals. State drug controllers are expected to monitor whether the revised rates are being followed.
NOT EVERY EXPENSIVE CANCER DRUG WILL BECOME CHEAPER
Although the announcement is a major step towards reducing medicine costs, its benefits will not extend to every cancer patient.
The price intervention applies to selected non-scheduled medicines and the specific brands and formulations covered by the revised notification. Expensive cancer treatments outside this list will not automatically become cheaper.
A report published by The Economic Times on October 29 noted that several costly patented treatments, including Keytruda (pembrolizumab), Opdyta (nivolumab) and Tagrisso (osimertinib), were not included in the latest price reductions.
This is particularly important for patients who depend on newer targeted therapies and immunotherapy treatments. While certain medicines within these treatment categories may be covered, the actual benefit depends on the specific product and brand listed by the NPPA.
Patients should therefore check the revised list rather than assume that all medicines belonging to a particular treatment category have received a price cut.
Healthcare experts have also pointed out that controlling trade margins alone may not solve the wider problem of expensive medicines. Patented drugs, limited competition and high development costs can continue to keep certain treatments beyond the reach of many families.
The latest announcement is an important pricing intervention, but making cancer care affordable will require broader efforts.
RISKS AND KEY ISSUES TO WATCH
Despite the expected benefits, several challenges could influence how much patients actually save.
1. Unequal benefits for patients: Those using medicines included in the revised list could see considerable savings. Patients relying on excluded or unchanged treatments may not experience immediate relief.
2. Implementation at pharmacies and hospitals: The revised prices must be correctly applied from November 9. Patients will need to check whether retailers and hospitals have updated their billing systems.
3. Availability of medicines: Manufacturers have been asked to maintain supplies, but regulators will need to monitor distribution to prevent shortages.
4. Affordability of patented treatments: Expensive patented cancer medicines remain a major concern, particularly where there is little competition and prices have not changed.
5. Further updates to the price list: The NPPA may publish additional information as pharmaceutical companies submit revised prices. Patients should refer to the latest available list.
6. Continuity of treatment: Patients should continue following their prescribed treatment plans and consult their doctors before considering any changes based on medicine prices.
WHAT TO WATCH NEXT
November 9 implementation: The revised prices are expected to come into effect nationwide. Updated MRPs at retail pharmacies and hospital pharmacies will be an important indicator of the policy's implementation.
NPPA compliance monitoring: The pricing authority and state drug controllers will play a key role in ensuring that pharmacies and hospitals follow the revised rates.
Further additions to the price list: More brands and formulations could be included as manufacturers submit updated price information.
Actual savings for patients: The real impact of the decision will become clearer as patients begin purchasing medicines at the revised prices.
Future action on patented medicines: The affordability of expensive cancer treatments that remain outside the latest revision is likely to continue attracting attention.
FACT CHECK METER
97% — STRONGLY SUPPORTED
Editorial assessment based on available official announcements and published reporting. This is not a statistical probability.
CONFIRMED DETAILS
The NPPA released revised MRPs for 543 anti-cancer medicine brands on October 28, 2026.
The revised prices are scheduled to take effect on November 9, 2026.
The trade-margin cap applies to 137 identified non-scheduled anti-cancer medicines, with margins restricted to 30% of the MRP.
The government estimates that the broader intervention could generate annual savings of approximately ₹2,500 crore for patients and their families.
IMPORTANT DISTINCTIONS
The 543 entries represent different brands and product variations, not 543 entirely separate medicines.
The projected savings are government estimates and should not be treated as guaranteed savings for every patient.
Some expensive patented treatments remain outside the price reductions reported in the latest revision.
Patients must verify the exact brand, strength, formulation and pack size before expecting a lower price.
AWX VERDICT
The government's decision marks a significant step towards making selected cancer medicines more affordable in India. However, the actual impact will depend on how effectively the revised prices are implemented, whether medicine supplies remain stable and which treatments individual patients require.
The announcement brings hope for meaningful financial relief, but it does not solve every affordability challenge in cancer care.
THE AWX BOTTOM LINE
India's decision to revise the prices of 543 cancer medicine brands could bring welcome relief to patients and families struggling with the rising cost of treatment.
From November 9, selected cancer medicines will be available at lower MRPs, with some products seeing exceptionally large price reductions. For patients who rely on these medicines, the savings could make a real difference to their monthly treatment expenses.
But the announcement is only the beginning. Pharmacies and hospitals must implement the revised prices, manufacturers must maintain reliable supplies, and regulators must ensure that the new rules are followed.
For patients and caregivers, the most important step is to check whether their prescribed medicine is included in the revised list and discuss any suitable alternatives with their oncologist.
Lower medicine prices are an important part of making cancer treatment accessible. Lasting relief, however, will depend on affordable medicines, reliable availability and continued efforts to bring down the overall cost of cancer care.
ATTLAS NEWS | AWX WORLD NEWS
Real Stories. Lasting Impact.
Comments
No comments yet.